ImpediMed Limited · ASX:IPD
ImpediMed — Shareholder Meeting (November 2026)
16 slides from ImpediMed's shareholder meeting presentation, Nov 18, 2026
Slide 1: 2026 Annual General Meeting – CEO's Presentation
ImpediMed Limited For personal use only Suite 31C, 12-18 Tryon Rd Lindfield NSW 2070 Australia E: investorrelations@impedimed.com W : impedimed.com 18 November 2026 Companies Announcements Office Australian Securities Exchange 2026 Annual General Meeting – CEO’s Presentation ImpediMed Limited (Imped
Slide 2: ImpediMed Limited 2026
rsonal use only ImpediMed Limited 2026 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited. 1
Slide 3: CEO's Presentation
CEO’s Presentation rsonal use only Mr Erik Anderson Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited. 2
Slide 4: The SOZO Digital Health Platform Value Proposition
The SOZO® Digital Health Platform Value Proposition Strong foundation rsonal use only • Best-in-class, FDA-cleared, TGA-cleared, and CE-Marked cloud-based digital health platform delivering body composition and fluid outputs, led by new Executive Leadership. Addressing fast growing healthcare segmen
Slide 5: The Cancer Survivorship Challenge
The Cancer Survivorship Challenge Lymphedema is reversible at the subclinical stage, and weight alone misses muscle loss 1,2 rsonal use only BREAST CANCER 4.3M 1 in 5 1 in 3 $22 - 40K US breast cancer survivors 3 develop lymphedema without develop sarcopenia in chemo, Annual cost of treatment per BI
Slide 6: Beyond Breast Cancer
Beyond Breast Cancer ALL CANCERS Patients with sarcopenia before treatment, by cancer type 5 rsonal use only Prostate 60% >18M 58% Lung (non-small cell) 43% at risk for developing limb US cancer survivors1 lymphedema2 Gynecologic⁶ 39% Colorectal 38% up to 83% ~60% Head and neck 31% of older patients
Slide 7: The Leader in Objective Survivorship Monitoring
The Leader in Objective Survivorship Monitoring SOZO® is advancing a new standard for By bringing greater clarity to aspects of rsonal use only understanding patient health throughout patient health that are often difficult to the cancer journey. Through objective recognize early, SOZO® helps care t
Slide 8: One Platform. Multiple Dimensions of Patient Health.
One Platform. Multiple Dimensions of Patient Health. rsonal use only L-Dex® Analysis BodyComp Analysis Objective assessment of lymphedema A broader view of survivorship health ✓ Baseline assessment ✓ FluidFit – fluid status ✓ Routine surveillance ✓ TissueFit – muscle and fat ✓ Long-term monitoring ✓
Slide 9: Two Market Segments. Two Roles in Cancer Care.
Two Market Segments. Two Roles in Cancer Care. Academic centers are where cancer care is invented. Community oncology is where most of it is delivered. rsonal use only Academic Cancer Community Oncology Centers Where care is invented Where care is delivered Who they are University-linked hospitals:
Slide 10: The Direction of Survivorship Care
The Direction of Survivorship Care Across oncology, clinical guidelines, accreditation standards, and supportive care initiatives are increasingly aligned around earlier detection, intervention, and long-term survivorship management. rsonal use only NCCN NAPBC Commission on Cancer ASCO Survivorship
Slide 11: Longitudinal Monitoring From Baseline Through Survivorship
Longitudinal Monitoring From Baseline Through Survivorship A single measurement is a snapshot. Repeated over time, it becomes a trend clinicians can act on. rsonal use only Pre-Treatment During Treatment Post-Treatment Long-Term Baseline Surveillance Recovery Survivorship L-Dex® Analysis Pre-op base
Slide 12: Heart Health
Heart Health • Building clinical and commercial momentum in the US outpatient rsonal use only heart failure monitoring market. • 50% of heart failure patients are overweight or obese, and 20% of patients are at elevated sarcopenia risk, ® drawing connection to use of BodyComp alongside HF-Dex for th
Slide 13: Weight Management & Body Composition
Weight Management & Body Composition • Addressing four key market segments where BodyComp rsonal use only clinical indications provide meaningful clinical relevance: • Primary/Preventive Care • Longevity & Wellness • Medically Managed Weight Loss • Sports Medicine & Research • New Strategic KOL & di
Slide 14: Right Leadership Team
Right Leadership Team: rsonal use only Erik Anderson Nicole Stout, DPT Erik Johnson Blake Ahitow Gina Kimball Managing Director & CEO Head of Sales Sr. Director, Customer Head of Commercial Ops Chief Clinical Innovation Officer Success & Strategic Accts McGregor Grant Scott Savage Julie Kuhlken Chel
Slide 15: Introducing SOZO Health
® Introducing SOZO Health rsonal use only ® SOZO Health is the pioneer and leader in precision fluid and body composition technology. We reveal meaningful health signals in the body before they can be seen or felt with advanced bioimpedance spectroscopy (BIS) technology that detects even the smalles
Slide 16: The Future for SOZO Health
® The Future for SOZO Health rsonal use only We empower longer, healthier lives by revealing essential health insights that enable early, proactive intervention. Our goal is to be THE trusted, essential vital sign for understanding fluid and body composition across the continuum of health and patien